Trial · NCT06552429
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 24
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Maximum concentration (Cmax) | week1,4, 8, 12, 24, 36, 48, 60, 72, 84, 96. | |
| Primary | Time to maximum concentration (Tmax) | week1,4, 8, 12, 24, 36, 48, 60, 72, 84, 96. | |
| Primary | Area under the plasma concentration-time curve | week1,4, 8, 12, 24, 36, 48, 60, 72, 84, 96. | |
| Primary | Apparent volume of distribution after oral administration (Vz/f) | week1,4, 8, 12, 24, 36, 48, 60, 72, 84, 96. | |
| Primary | Apparent plasma clearance (CL/F) | week1,4, 8, 12, 24, 36, 48, 60, 72, 84, 96. | |
| Primary | Plasma elimination half-life (t1/2) | week1,4, 8, 12, 24, 36, 48, 60, 72, 84, 96. | |
| Primary | Relationship between exposure and the effect (desired-effectiveness or undesirable-toxicity) in a pharmacokinetic model and pharmacodynamic model. | up to 96 weeks. | |
| Secondary | Rate of complete hematological remission. | Week 24, 36, 48, 60, 72, 84, 96. | |
| Secondary | Platelet counts change from baseline. | Week 12, 24, 36, 48, 60, 72, 84, 96. | |
| Secondary | White blood cell counts change from baseline. | Week 12, 24, 36, 48, 60, 72, 84, 96. | |
| Secondary | Complete remission rate. | Week 24, 36, 48, 60, 72, 84, 96. | |
| Secondary | Time to complete remission from baseline. | Week 48, 96. | |
| Secondary | Duration of complete remission. | Week 48, 96. | |
| Secondary | Remission rate of bone marrow. | Week 48, 96. | |
| Secondary | Incidence of disease progression. | Week 48, 96. | |
| Secondary | Change of JAK2V617F mutations load from baseline. | Week 48, 96. | JAK2V617F mutations were quantitatively detected using next-generation sequencing |
| Secondary | Change of CALR mutations load from baseline. | Week 48, 96. | CALR mutations were quantitatively detected using next-generation sequencing |
| Secondary | Change of MPL mutations load from baseline. | Week 48, 96. | MPL mutations were quantitatively detected using next-generation sequencing |
| Secondary | Change of MPN-SAF TSS scores from baseline | Week 12, 24, 36, 48, 60, 72, 84,96. | |
| Secondary | Change of spleen size from baseline | Week 12, 24, 36, 48, 60, 72, 84, 96. | The maximum length of the spleen was measured by ultrasound. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06552429/registered